Intended for U.S. Audiences Full Prescribing Information including Medication Guide Patients

Letybo® (letibotulinumtoxinA-wlbg) is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

15+ Years of clinical experience

44+ Million Treatments2

70+ Countries3

The Standard in K-Beauty

2 Data on file. Total toxin sales 2010–2026. Hugel; May 2026.    3 Data on file. List of approved countries. Hugel Inc. 2026.

Reliable Outcomes

Validated in Extensive Clinical Studies

Composite Score65%

None or mild on the Glabellar Line Scale.

Composite GLS endpoint · BLESS III
Investigator Assessment79%

≥2 grade improvement per investigator.

vs. 1% for placebo
Subject Assessment69%

≥2 grade improvement per subject.

vs. 0% for placebo
Review results from U.S. phase 3 study → Contact Medical Affairs

In other studies, Letybo® met the primary endpoint composite responder rate at 47% and 45%.

1 Proportion of subjects achieving score of 0 or 1 (none or mild) and ≥2 grade improvement from baseline at maximum frown at Week 4, as assessed independently by both investigator and subject on the Glabellar Line Scale (GLS), a 4-point grading scale (0=none, 1=mild, 2=moderate, 3=severe). Study subjects (with moderate to severe glabellar lines at maximum frown at baseline) received either 20 units Letybo or an equal volume of placebo. Efficacy demonstrated in 3 international phase III trials: identically designed, randomized, multi-center, double blind, placebo-controlled studies.

Proven results, backed by data and clinical experience

Honor before Letybo treatment
Honor 3 days after Letybo treatment
BEFORE AFTER
Actual Letybo patient in her 30s.
After (Day 3)
Tara before Letybo treatment
Tara 3 days after Letybo treatment
BEFORE AFTER
Actual Letybo patient in her 30s.
After (Day 3)
Michael before Letybo treatment
Michael 16 weeks after Letybo treatment
BEFORE AFTER
Actual Letybo patient in his 40s.
After (4 weeks)
Patient before Letybo treatment
Patient 4 months after Letybo treatment
BEFORE AFTER
Actual Letybo patient in her 50s.
After (4 months)

Actual patients at maximum frown. Unretouched photos. Individual results may vary.

Visible results in 1–3 days*

*In a Phase 3 clinical study, 24% of Letybo patients reported seeing improvement after 1 day, with 75% of patients reporting improvement after 3 days.4

Lasting up to 4 months**

**On average, Letybo patients received 3 treatments per year.5

FDA
Approved

Used by millions of patients and providers worldwide before reaching U.S. clinics.

Across 3 clinical studies in 1,200+ patients, the majority of patients treated with Letybo observed full results by week 4 (≥2 grade improvement) by physician and patient assessments.5

4 Mueller DS, Prinz V, Adelglass J, Cox SE, Gold MH, et al. Efficacy and safety of letibotulinumtoxinA in the treatment of glabellar lines: a randomized multicenter, placebo-controlled Phase 3 study. ASJ. 2022:42(6):677-688. Doi: 10.1093/asj/sjac019.

5 LETYBO (letibotulinumtoxinA-wlbg) for injection, for intramuscular use. Prescribing information. Chuncheon, Korea; Hugel, Inc.

Ready
to see what Letybo® can do for you and your practice?

Complete the form below and a sales representative will be in touch shortly.

Contact Sales →

INDICATION

LETYBO® is a prescription medicine for adults that is injected into muscles to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).

IMPORTANT SAFETY INFORMATION

LETYBO® may cause serious side effects that can be life threatening. Call your healthcare provider or get medical help right away if you have any of these problems after treatment with LETYBO®:

Problems swallowing, speaking, or breathing, due to weakening of associated muscles can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.

Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms that include loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

Do not receive LETYBO® if you are allergic to any of the ingredients in LETYBO® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as MYOBLOC® (rimabotulinumtoxinB), BOTOX®/BOTOX® COSMETIC (onabotulinumtoxinA), DYSPORT® (abobotulinumtoxinA), XEOMIN® (incobotulinumtoxinA), JEUVEAU® (prabotulinumtoxinA-xvfs), or DAXXIFY® (daxibotulinumtoxinA-lanm); or have a skin infection at the planned injection site.

LETYBO® dosing units are not the same as, or comparable to, any other botulinum toxin product.

Tell your healthcare provider about all your medical conditions, including side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles, drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using LETYBO® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received LETYBO® in the past.

Especially tell your healthcare provider if you have received any other botulinum toxin product in the last 4 months or any in the past, and exactly which product you received (such as MYOBLOC®, BOTOX®/BOTOX® COSMETIC, DYSPORT®, XEOMIN®, JEUVEAU®, or DAXXIFY®). LETYBO® may cause serious side effects, including allergic reactions (such as itching, rash, hives, wheezing, trouble breathing, or dizziness or feeling faint), heart problems (such as irregular heartbeat and heart attack), and eye problems (including dry eye, reduced blinking, and corneal problems). Tell your healthcare provider or get help right away if you experience a serious side effect. No serious side events of distant spread of toxin effect associated with dermatologic use of LETYBO® have been reported in clinical studies at the dose of 20 Units for glabellar lines. The most common side effect of LETYBO® was headache.

These are not all the possible side effects of LETYBO®. For more information, see the full Prescribing Information including Boxed Warning, and refer to the Medication Guide or talk with your doctor. To report side effects associated with LETYBO®, please call 1-877-390-2906. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Certain images in this material were created using artificial intelligence for illustrative purposes only. Before and After imagery is unretouched and represents actual patients.